← Back to patent-cliff list
Dexamethasone sodium phosphate injectable gel (Scilex Holding)
Tier C — Watch / tradeDexamethasone sodium phosphate injectable gel (Scilex Holding)
Semnur Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR
Brand：SEMDEXA
Indications (approved)：坐骨神经痛
Regional status
US
Phase III
2017-12-08
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexamethasone sodium phosphate injectable gel (Scilex Holding)?
Approved indications include: 坐骨神经痛.
When does the Dexamethasone sodium phosphate injectable gel (Scilex Holding) patent expire?
No public expiry year is available for Dexamethasone sodium phosphate injectable gel (Scilex Holding) yet; this page updates once verified.
How do I get a quote for Dexamethasone sodium phosphate injectable gel (Scilex Holding) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09